

03CD

Patent  
Attorney's Docket No. 018995-452



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of )  
Nishizumi NISHIMUTA et al. ) Group Art Unit: Unassigned  
Application No.: 10/046,575 ) Examiner: Unassigned  
Filed: January 16, 2002 )  
For: EXTERNAL PREPARATION FOR SKIN )  
DISEASES CONTAINING )  
NITROIMIDAZOLE )

**INFORMATION DISCLOSURE STATEMENT  
TRANSMITTAL LETTER**

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:


Enclosed is an Information Disclosure Statement and accompanying form PTO-1449 for the above-identified patent application.

- No additional fee for submission of an IDS is required.
- The fee of \$180.00 (126) as set forth in 37 C.F.R. § 1.17(p) is also enclosed.
- A certification under 37 C.F.R. § 1.97(e) is also enclosed.
- A certification under 37 C.F.R. § 1.97(e), and the fee of \$180.00 (126) as set forth in 37 C.F.R. § 1.17(p) are also enclosed.
- Charge \$ \_\_\_\_\_ to Deposit Account No. 02-4800 for the fee due.
- A check in the amount of \$ \_\_\_\_\_ is enclosed for the fee due.

The Commissioner is hereby authorized to charge any appropriate fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 02-4800. This paper is submitted in duplicate.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

By:   
Dawn M. Gardner  
Registration No. 44,118

P.O. Box 1404  
Alexandria, Virginia 22313-1404  
(703) 836-6620

Date: April 16, 2002

Patent  
Attorney's Docket No. 018995-452

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of )  
Nishizumi NISHIMUTA et al. ) Group Art Unit: Unassigned  
Application No.: 10/046,575 ) Examiner: Unassigned  
Filed: January 16, 2002 )  
For: EXTERNAL PREPARATION FOR SKIN )  
DISEASES CONTAINING )  
NITROIMIDAZOLE )



**INFORMATION DISCLOSURE STATEMENT**

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

In accordance with the duty of disclosure as set forth in 37 C.F.R. § 1.56, Applicants hereby submit the following information in conformance with 37 C.F.R. §§ 1.97 and 1.98.

Pursuant to 37 C.F.R. § 1.98, a copy of each of the documents cited is enclosed.

**FOREIGN PATENTS**

1. LACHARRIERE et al., Japanese Patent Publication No. 07304649 A, published on November 21, 1995, with attached English language abstract.
2. TATSUTAKE et al., Japanese Patent Publication No. 07025784 A, published on January 27, 1995, with attached English language abstract.
3. AKIRA et al., Japanese Patent Publication No. 06227989 A, published on August 16, 1994, with English language abstract.
4. SOO et al., Japanese Patent Publication No. 10007584 A, published on January 13, 1998, with English language abstract.

**NON PATENT LITERATURE DOCUMENTS**

1. BOYD et al., "An investigation of the Immunosuppressive Effects of Niridazole and Metronidazole in Rat and Baboon Heterotopic Cardiac Allograft Models," *Transplantation*, 1981, pp. 326-329, vol. 31, no. 5, Lippincott William & Wilkins, Baltimore, Maryland.
2. YOURAN, "Summary of Drugs," 1992, pp. 1194-1195, vol. 5.
3. NIPPON YAKYOKUHOU KAISETSUSYO, Explanation of Japanese Codices No. 13 revision, c-2544, 1996.
4. Report of experimental results made by Dr. Hirahara, dated October 10, 2001.
5. Kiso to Rinsho, pp. 2693-2700, vol. 31, no. 8, 1997.
6. "Definition and diagnostic standard of atopic dermatitis," *Japanese Society of Dermatology*, 1994, p. 1210, vol. 104.
7. A guideline for the treatment of atopic dermatitis, 2001.
8. Today's Therapy in Dermatology, 1996, pp. 179-182.
9. *Japanese Journal of Dermatology*, 2000, p. 667, vol. 110, No. 4.
10. HIHU, *West Japan Dermatology*, 1997, pp. 58-65, vol. 59, published by Ointment study group.
11. ZASSHI, *Journal of the Japanese Medicine*, 2001, pp. 53-57, vol. 126, no. 1.
12. KOSTAKIS et al., "The Immunosuppressive Action of Metronidazole," *IRCS Medical Science: Cardiovascular System: Immunology and Allergy: Pharmacology: Surgery and Transplantation*, 1997, vol. 142, no. 5.

The documents are being submitted within 3 months of the filing or entry of the national stage of this application or before the first Office Action on the merits, whichever is later, therefore no fee or statement is required under 37 C.F.R. § 1.97(b).


Information Disclosure Statement  
Application Serial No. 10/046,575  
Attorney's Docket No. 018995-452  
Page 3

To assist the Examiner, the documents are listed on the attached form PTO-1449. It is respectfully requested that an Examiner initialed copy of this form be returned to the undersigned.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

By:

  
Dawn M. Gardner  
Registration No. 44,118

P.O. Box 1404  
Alexandria, Virginia 22313-1404  
(703) 836-6620

Date: April 16, 2002